Pub Date : 2024-09-25DOI: 10.1016/j.oor.2024.100663
Background
Sebaceous adenoma of the salivary glands are uncommon benign neoplasms, comprising about 0.1 % of salivary tumors. These tumors can be difficult to recognize with heterogeneous appearance on imaging.
Case report
A 67-year-old man presented with a painless, progressively growing left parotid mass. Imaging showed a heterogenous, partially cystic mass in the superficial and deep lobes of the parotid with some areas of adipose density. Intraoperatively, a mass with sebaceous differentiation was found to be encasing the main trunk and pes anserinus of the facial nerve, requiring nerve sacrifice for en bloc resection. Final pathology revealed a sebaceous adenoma with intense xanthomatous reaction compressing the facial nerve.
Conclusion
Although benign and associated with little risk of recurrence, sebaceous adenomas may be difficult to recognize on preoperative workup and may be locally aggressive. Complete surgical resection is the mainstay of therapy, but rehabilitation may be required in the event of facial nerve involvement.
{"title":"Sebaceous adenoma of the parotid gland encasing the facial nerve: Case report and review of the literature","authors":"","doi":"10.1016/j.oor.2024.100663","DOIUrl":"10.1016/j.oor.2024.100663","url":null,"abstract":"<div><h3>Background</h3><div>Sebaceous adenoma of the salivary glands are uncommon benign neoplasms, comprising about 0.1 % of salivary tumors. These tumors can be difficult to recognize with heterogeneous appearance on imaging.</div></div><div><h3>Case report</h3><div>A 67-year-old man presented with a painless, progressively growing left parotid mass. Imaging showed a heterogenous, partially cystic mass in the superficial and deep lobes of the parotid with some areas of adipose density. Intraoperatively, a mass with sebaceous differentiation was found to be encasing the main trunk and pes anserinus of the facial nerve, requiring nerve sacrifice for en bloc resection. Final pathology revealed a sebaceous adenoma with intense xanthomatous reaction compressing the facial nerve.</div></div><div><h3>Conclusion</h3><div>Although benign and associated with little risk of recurrence, sebaceous adenomas may be difficult to recognize on preoperative workup and may be locally aggressive. Complete surgical resection is the mainstay of therapy, but rehabilitation may be required in the event of facial nerve involvement.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142327036","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-19DOI: 10.1016/j.oor.2024.100653
Objective
In the United States, pharyngeal cancer has become the most common type of head and neck cancer, with 80 % of cases found in males. Although disparities in treatment delays have been observed in pharyngeal patients, less is known about how policies facilitate timely care. This study aimed to estimate the association between Medicaid expansion and delaying initiation of pharyngeal cancer treatment.
Methodology
We extracted Surveillance, Epidemiological, End Results (SEER) case data to analyze pharyngeal cancers diagnosed between 2000 and 2018. The outcome of interest was a binary variable indicating if the patient initiated treatment two or more months after diagnosis. We conducted subgroup analyses by sex, marital status, and type of treatment received (surgery, radiation, chemotherapy, post-operative radiation, systemic therapy). We implemented the Matrix Completion algorithm to account for staggered rollout of Medicaid expansion within our difference-in-differences design.
Results
Our sample included 79,433 patients diagnosed with pharynx cancer. Delayed treatment was lowest among married females receiving systemic therapy (5 %), and highest among married males and females not recommended to receive surgery (43 %). Generally, there was no association between Medicaid expansion and changes in delayed treatment. Subgroup analyses show that Medicaid expansion was associated with reduced treatment delays in unmarried females receiving systemic therapy (−4.5%-points), and married males receiving chemotherapy (Est. = −2.6%-points), radiotherapy (Est. = −3.1%-points), and married males not recommended to receive surgery (Est. = −4.6%-points).
Conclusions
Given the importance of timely pharyngeal cancer treatment, health systems must identify and address the drivers of treatment delays to advance cancer equity.
{"title":"Sex & marital differences in delayed pharyngeal cancer treatment before and after medicaid expansion","authors":"","doi":"10.1016/j.oor.2024.100653","DOIUrl":"10.1016/j.oor.2024.100653","url":null,"abstract":"<div><h3>Objective</h3><p>In the United States, pharyngeal cancer has become the most common type of head and neck cancer, with 80 % of cases found in males. Although disparities in treatment delays have been observed in pharyngeal patients, less is known about how policies facilitate timely care. This study aimed to estimate the association between Medicaid expansion and delaying initiation of pharyngeal cancer treatment.</p></div><div><h3>Methodology</h3><p>We extracted Surveillance, Epidemiological, End Results (SEER) case data to analyze pharyngeal cancers diagnosed between 2000 and 2018. The outcome of interest was a binary variable indicating if the patient initiated treatment two or more months after diagnosis. We conducted subgroup analyses by sex, marital status, and type of treatment received (surgery, radiation, chemotherapy, post-operative radiation, systemic therapy). We implemented the Matrix Completion algorithm to account for staggered rollout of Medicaid expansion within our difference-in-differences design.</p></div><div><h3>Results</h3><p>Our sample included 79,433 patients diagnosed with pharynx cancer. Delayed treatment was lowest among married females receiving systemic therapy (5 %), and highest among married males and females not recommended to receive surgery (43 %). Generally, there was no association between Medicaid expansion and changes in delayed treatment. Subgroup analyses show that Medicaid expansion was associated with reduced treatment delays in unmarried females receiving systemic therapy (−4.5%-points), and married males receiving chemotherapy (Est. = −2.6%-points), radiotherapy (Est. = −3.1%-points), and married males not recommended to receive surgery (Est. = −4.6%-points).</p></div><div><h3>Conclusions</h3><p>Given the importance of timely pharyngeal cancer treatment, health systems must identify and address the drivers of treatment delays to advance cancer equity.</p></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004990/pdfft?md5=664276d5ddc4f7bf3248c61ca505846e&pid=1-s2.0-S2772906024004990-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142274871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-19DOI: 10.1016/j.oor.2024.100654
Brachytherapy has become integral to the treatment of oral cancers, offering the advantage of delivering high doses of radiation directly to tumors while minimizing exposure to surrounding healthy tissues. This review examines recent advancements that have significantly improved the precision and effectiveness of brachytherapy. The integration of high-resolution imaging technologies, such as MRI and CT scans, has enhanced tumor delineation, enabling more accurate placement of radioactive sources. Innovations in radioactive sources, particularly high-dose-rate (HDR) brachytherapy, have optimized radiation delivery, leading to shorter treatment durations and improved patient outcomes. Personalized treatment approaches, guided by genomic and molecular profiling, allow for customized dosimeter, maximizing therapeutic effectiveness while minimizing toxicity. Additionally, combining brachytherapy with other treatment modalities such as surgery, external beam radiation therapy (EBRT), and chemotherapy has demonstrated synergistic benefits, improving local control and reducing recurrence rates. Despite its advantages, brachytherapy faces challenges, including the invasive nature of the procedure, the need for specialized equipment and training, and limitations related to tumor size. Future directions in the field include advancements in imaging and dosimeter, the development of robotic-assisted brachytherapy, and more personalized treatment plans. These innovations promise to refine brachytherapy further and expand its applicability. This review highlights the transformative potential of recent advances in brachytherapy, emphasizing its evolving role in the localized treatment of oral cancers.
{"title":"Radiant advances: The future of brachytherapy in oral oncology","authors":"","doi":"10.1016/j.oor.2024.100654","DOIUrl":"10.1016/j.oor.2024.100654","url":null,"abstract":"<div><div>Brachytherapy has become integral to the treatment of oral cancers, offering the advantage of delivering high doses of radiation directly to tumors while minimizing exposure to surrounding healthy tissues. This review examines recent advancements that have significantly improved the precision and effectiveness of brachytherapy. The integration of high-resolution imaging technologies, such as MRI and CT scans, has enhanced tumor delineation, enabling more accurate placement of radioactive sources. Innovations in radioactive sources, particularly high-dose-rate (HDR) brachytherapy, have optimized radiation delivery, leading to shorter treatment durations and improved patient outcomes. Personalized treatment approaches, guided by genomic and molecular profiling, allow for customized dosimeter, maximizing therapeutic effectiveness while minimizing toxicity. Additionally, combining brachytherapy with other treatment modalities such as surgery, external beam radiation therapy (EBRT), and chemotherapy has demonstrated synergistic benefits, improving local control and reducing recurrence rates. Despite its advantages, brachytherapy faces challenges, including the invasive nature of the procedure, the need for specialized equipment and training, and limitations related to tumor size. Future directions in the field include advancements in imaging and dosimeter, the development of robotic-assisted brachytherapy, and more personalized treatment plans. These innovations promise to refine brachytherapy further and expand its applicability. This review highlights the transformative potential of recent advances in brachytherapy, emphasizing its evolving role in the localized treatment of oral cancers.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024005004/pdfft?md5=de4d017ee953f597078b5dc22e05f558&pid=1-s2.0-S2772906024005004-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-19DOI: 10.1016/j.oor.2024.100659
Oropharyngeal cancer (OPC) has seen significant advancements in treatment modalities, particularly with the integration of radiotherapy and systemic therapies. This review comprehensively examines recent developments in combining these treatments, focusing on their synergistic potential, clinical outcomes, and future prospects. Advances in radiotherapy, including intensity-modulated radiotherapy (IMRT), proton beam therapy (PBT), and stereotactic body radiotherapy (SBRT), have improved targeting and reduced toxicity. Concurrent chemoradiotherapy (CCRT) remains a cornerstone, while the onset of immunotherapy, especially immune checkpoint inhibitors, has transformed systemic treatment. Combining radiotherapy with immunotherapy shows promise in enhancing treatment efficacy. Targeted therapies, such as those targeting the epidermal growth factor receptor (EGFR), are also explored for their potential in OPC management. The review underscores the importance of personalized treatment approaches and highlights ongoing research into novel therapeutic combinations and advanced technologies like artificial intelligence and machine learning. These advancements aim to optimize treatment strategies, improve survival rates, and minimize treatment-related toxicity, heralding a new era in OPC management.
{"title":"Combining radiotherapy and systemic therapies in oropharyngeal cancer: A comprehensive review of recent developments","authors":"","doi":"10.1016/j.oor.2024.100659","DOIUrl":"10.1016/j.oor.2024.100659","url":null,"abstract":"<div><div>Oropharyngeal cancer (OPC) has seen significant advancements in treatment modalities, particularly with the integration of radiotherapy and systemic therapies. This review comprehensively examines recent developments in combining these treatments, focusing on their synergistic potential, clinical outcomes, and future prospects. Advances in radiotherapy, including intensity-modulated radiotherapy (IMRT), proton beam therapy (PBT), and stereotactic body radiotherapy (SBRT), have improved targeting and reduced toxicity. Concurrent chemoradiotherapy (CCRT) remains a cornerstone, while the onset of immunotherapy, especially immune checkpoint inhibitors, has transformed systemic treatment. Combining radiotherapy with immunotherapy shows promise in enhancing treatment efficacy. Targeted therapies, such as those targeting the epidermal growth factor receptor (EGFR), are also explored for their potential in OPC management. The review underscores the importance of personalized treatment approaches and highlights ongoing research into novel therapeutic combinations and advanced technologies like artificial intelligence and machine learning. These advancements aim to optimize treatment strategies, improve survival rates, and minimize treatment-related toxicity, heralding a new era in OPC management.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024005053/pdfft?md5=f9ee3f5b239d8f01f715ac3afe275945&pid=1-s2.0-S2772906024005053-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142312627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-18DOI: 10.1016/j.oor.2024.100652
Recent advances in cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy, have significantly improved the clinical management of various cancers. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, enhance the body's immune response against tumors, offering substantial benefits in cancers like melanoma, non-small-cell lung cancer, and lymphoma. CAR-T cell therapy has demonstrated remarkable efficacy in hematologic malignancies, particularly B-cell leukemias and lymphomas, through the genetic modification of T-cells to target tumor-specific antigens.Despite these successes, several challenges remain, particularly in the treatment of solid tumors. The heterogeneity of tumor antigens, the presence of physical barriers that impede CAR-T cell infiltration, and the immunosuppressive tumor microenvironment limit the effectiveness of these therapies. To address these issues, ongoing research is exploring combination therapies that integrate ICIs with CAR-T cell therapy, improved CAR-T cell engineering, and strategies to modulate the tumor microenvironment to enhance immune cell infiltration and function.
癌症免疫疗法的最新进展，包括免疫检查点抑制剂（ICIs）和嵌合抗原受体（CAR）T 细胞疗法，大大改善了各种癌症的临床治疗。PD-1/PD-L1和CTLA-4抑制剂等ICIs能增强机体对肿瘤的免疫反应，对黑色素瘤、非小细胞肺癌和淋巴瘤等癌症大有裨益。CAR-T 细胞疗法通过对 T 细胞进行基因改造，使其针对肿瘤特异性抗原，在血液系统恶性肿瘤，尤其是 B 细胞白血病和淋巴瘤方面取得了显著疗效。肿瘤抗原的异质性、阻碍 CAR-T 细胞浸润的物理屏障的存在以及免疫抑制性肿瘤微环境限制了这些疗法的有效性。为了解决这些问题，目前的研究正在探索将 ICIs 与 CAR-T 细胞疗法相结合的联合疗法、改进的 CAR-T 细胞工程以及调节肿瘤微环境以增强免疫细胞浸润和功能的策略。
{"title":"Current advances in immunotherapy for cancer","authors":"","doi":"10.1016/j.oor.2024.100652","DOIUrl":"10.1016/j.oor.2024.100652","url":null,"abstract":"<div><div>Recent advances in cancer immunotherapy, including immune checkpoint inhibitors (ICIs) and chimeric antigen receptor (CAR) T-cell therapy, have significantly improved the clinical management of various cancers. ICIs, such as PD-1/PD-L1 and CTLA-4 inhibitors, enhance the body's immune response against tumors, offering substantial benefits in cancers like melanoma, non-small-cell lung cancer, and lymphoma. CAR-T cell therapy has demonstrated remarkable efficacy in hematologic malignancies, particularly B-cell leukemias and lymphomas, through the genetic modification of T-cells to target tumor-specific antigens.Despite these successes, several challenges remain, particularly in the treatment of solid tumors. The heterogeneity of tumor antigens, the presence of physical barriers that impede CAR-T cell infiltration, and the immunosuppressive tumor microenvironment limit the effectiveness of these therapies. To address these issues, ongoing research is exploring combination therapies that integrate ICIs with CAR-T cell therapy, improved CAR-T cell engineering, and strategies to modulate the tumor microenvironment to enhance immune cell infiltration and function.</div></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004989/pdfft?md5=9b7ce80b933ef99a3f68538ac720b265&pid=1-s2.0-S2772906024004989-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142314667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-12DOI: 10.1016/j.oor.2024.100650
Oropharyngeal Squamous Cell Carcinoma (OPSCC) is a challenging subtype of head and neck cancer that traditionally has been associated with poor prognosis and high morbidity due to the limitations of conventional treatments such as surgery, radiation, and chemotherapy. Immune checkpoint inhibitors have revolutionized OPSCC and other cancer therapies. ICIs that target the PD-1 and PD-L1 axis and CTLA-4 have altered cancer action by improving the immune system capacity to detect and kill cancer cells. This paper discusses the significant impact of ICIs like Pembrolizumab and Nivolumab, which have been approved for use in recurrent or metastatic OPSCC and have demonstrated remarkable efficacy in clinical trials. The integration of these therapies into clinical practice has been facilitated by the identification of biomarkers such as PD-L1 expression, which guides personalized treatment strategies. Moreover, ongoing research into combination therapies involving ICIs and other treatment modalities is poised which, leads for further improvement in patient outcomes. Despite the successes, challenges such as immune-related adverse events and resistance mechanisms remain, underscoring the need for continued innovation and exploration in the field. This review highlights the pivotal role of ICIs in redefining OPSCC treatment, offering new hope for sustained survival and improved quality of life.
{"title":"Emerging immune checkpoint inhibitors for the treatment of oropharyngeal squamous cell carcinoma","authors":"","doi":"10.1016/j.oor.2024.100650","DOIUrl":"10.1016/j.oor.2024.100650","url":null,"abstract":"<div><p>Oropharyngeal Squamous Cell Carcinoma (OPSCC) is a challenging subtype of head and neck cancer that traditionally has been associated with poor prognosis and high morbidity due to the limitations of conventional treatments such as surgery, radiation, and chemotherapy. Immune checkpoint inhibitors have revolutionized OPSCC and other cancer therapies. ICIs that target the PD-1 and PD-L1 axis and CTLA-4 have altered cancer action by improving the immune system capacity to detect and kill cancer cells. This paper discusses the significant impact of ICIs like Pembrolizumab and Nivolumab, which have been approved for use in recurrent or metastatic OPSCC and have demonstrated remarkable efficacy in clinical trials. The integration of these therapies into clinical practice has been facilitated by the identification of biomarkers such as PD-L1 expression, which guides personalized treatment strategies. Moreover, ongoing research into combination therapies involving ICIs and other treatment modalities is poised which, leads for further improvement in patient outcomes. Despite the successes, challenges such as immune-related adverse events and resistance mechanisms remain, underscoring the need for continued innovation and exploration in the field. This review highlights the pivotal role of ICIs in redefining OPSCC treatment, offering new hope for sustained survival and improved quality of life.</p></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004965/pdfft?md5=1bba1c33fd8f844785a4d0d026540be8&pid=1-s2.0-S2772906024004965-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142274830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-10DOI: 10.1016/j.oor.2024.100648
{"title":"Letter to the editor, “Incidental dose to the oropharynx with involved neck only radiotherapy in squamous cell cancer of unknown primary of the head and neck.”","authors":"","doi":"10.1016/j.oor.2024.100648","DOIUrl":"10.1016/j.oor.2024.100648","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004941/pdfft?md5=6d662e12d0dcea6c5bcbd82bb662df25&pid=1-s2.0-S2772906024004941-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142274831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01DOI: 10.1016/j.oor.2024.100643
{"title":"Comment on “Prognostic significance of neutrophil to lymphocyte ratio (NLR) in oral squamous cell carcinoma”","authors":"","doi":"10.1016/j.oor.2024.100643","DOIUrl":"10.1016/j.oor.2024.100643","url":null,"abstract":"","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004898/pdfft?md5=0a1145f3988d84aa86ff9cbe5ba779f2&pid=1-s2.0-S2772906024004898-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142167796","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2024-09-01DOI: 10.1016/j.oor.2024.100636
Statement of problem
Whether prosthetic rehabilitation significantly affects quality of life and functions of post maxillectomy patients.
Objective
Systematically analyze the effects of different types of obturators on post-maxillectomy patients focusing on quality of life and function.
Materials and methods
An electronic search was conducted across four databases PubMed, Google Scholar, Cochrane Library, and ScienceDirect in English language from January 1995 June 2024 using the key terms maxillectomy OR hemi-maxillectomy OR palatomaxillary defect OR Aramany OR Brown OR Okay AND obturator OR denture OR prosthetic AND flap OR surgery OR prosthetic rehabilitation. Additionally, a hand search was performed in the institutional library on Journal of Prosthetic Dentistry, Journal of Indian Prosthodontic Society, Journal of Prosthodontics, International Journal of Prosthodontics and Indian Journal of Prosthodontic Research.
Results
Seven articles were included in this systematic review. Patient scores from quality-of-life questionnaires and functional ability evaluations were compared across a total of 251 patients, including those with and without obturators. The evaluation included 3 prospective studies, 2 retrospective studies, 1 clinical study, and 1 randomized controlled trial. The results demonstrated a statistically significant improvement in both speech and quality of life for patients using maxillary obturators.
Conclusion
Obturator prostheses are not only improved the health-related quality of life (HRQOL) but also enhance overall function of the patient rehabilitated with maxillary oncological defects. They play a crucial role in orofacial rehabilitation by addressing functional and aesthetic challenges faced by individuals with such defects. This positive impact is likely due to the prostheses' ability to restore oral and facial functions, improve speech, and enhance self-esteem and social interactions.
问题陈述假体康复是否会明显影响上颌骨切除术后患者的生活质量和功能。目的系统分析不同类型的闭孔器对上颌骨切除术后患者的影响，重点关注生活质量和功能。材料和方法使用关键术语上颌骨切除术或半上颌骨切除术或腭颌缺损或阿拉曼尼或布朗或Okay AND obturator OR denture OR prosthetic AND flap OR surgery OR prosthetic rehabilitation，对1995年1月至2024年6月期间的四个英文数据库PubMed、Google Scholar、Cochrane Library和ScienceDirect进行了电子检索。此外，还在机构图书馆对《口腔修复学杂志》、《印度口腔修复学会杂志》、《口腔修复学杂志》、《国际口腔修复学杂志》和《印度口腔修复研究杂志》进行了人工检索。对总共 251 名患者的生活质量问卷和功能能力评估结果进行了比较，其中包括使用和未使用顺铂的患者。评估包括 3 项前瞻性研究、2 项回顾性研究、1 项临床研究和 1 项随机对照试验。结果表明，使用上颌钝器的患者在言语和生活质量方面都有显著的统计学改善。它们在口面部康复中发挥着至关重要的作用，解决了此类缺损患者所面临的功能和美学挑战。这种积极影响可能是由于假体能够恢复口腔和面部功能、改善言语、增强自尊和社会交往。
{"title":"Role of obturator in restoring quality of life and function in maxillary oncological defect cases- A systematic review","authors":"","doi":"10.1016/j.oor.2024.100636","DOIUrl":"10.1016/j.oor.2024.100636","url":null,"abstract":"<div><h3>Statement of problem</h3><p>Whether prosthetic rehabilitation significantly affects quality of life and functions of post maxillectomy patients.</p></div><div><h3>Objective</h3><p>Systematically analyze the effects of different types of obturators on post-maxillectomy patients focusing on quality of life and function.</p></div><div><h3>Materials and methods</h3><p>An electronic search was conducted across four databases PubMed, Google Scholar, Cochrane Library, and ScienceDirect in English language from January 1995 June 2024 using the key terms maxillectomy OR hemi-maxillectomy OR palatomaxillary defect OR Aramany OR Brown OR Okay AND obturator OR denture OR prosthetic AND flap OR surgery OR prosthetic rehabilitation. Additionally, a hand search was performed in the institutional library on Journal of Prosthetic Dentistry, Journal of Indian Prosthodontic Society, Journal of Prosthodontics, International Journal of Prosthodontics and Indian Journal of Prosthodontic Research.</p></div><div><h3>Results</h3><p>Seven articles were included in this systematic review. Patient scores from quality-of-life questionnaires and functional ability evaluations were compared across a total of 251 patients, including those with and without obturators. The evaluation included 3 prospective studies, 2 retrospective studies, 1 clinical study, and 1 randomized controlled trial. The results demonstrated a statistically significant improvement in both speech and quality of life for patients using maxillary obturators.</p></div><div><h3>Conclusion</h3><p>Obturator prostheses are not only improved the health-related quality of life (HRQOL) but also enhance overall function of the patient rehabilitated with maxillary oncological defects. They play a crucial role in orofacial rehabilitation by addressing functional and aesthetic challenges faced by individuals with such defects. This positive impact is likely due to the prostheses' ability to restore oral and facial functions, improve speech, and enhance self-esteem and social interactions.</p></div>","PeriodicalId":94378,"journal":{"name":"Oral Oncology Reports","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2772906024004825/pdfft?md5=00a0a09c92a0e72a9d18b68ff8673947&pid=1-s2.0-S2772906024004825-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142129270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号